Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Fox

Showing results (61-70 of 119) with videos related to

Pageof 12
Sort By:
Cancer Prevention Research (Philadelphia, Pa.)|July 8, 2011
Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer familiesHeather Thorne, Amber J Willems, Eveline Niedermayr, et al.
The Lancet. Oncology|December 15, 2016
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA studyStephen J Luen, Roberto Salgado, Stephen Fox, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|November 6, 2010
Establishment of the Australian in situ hybridization program for the assessment of HER2 amplification in breast cancer: a model for the introduction of new biomarkers into clinical practiceGelareh Farshid, Jane E Armes, Richard Bell, et al.
International Journal of Clinical and Experimental Pathology|January 1, 2015
Blood vessel invasion and other variables as predictors of long-term survival in Japanese and British patients with primary invasive breast cancerTakao Kato, Francesco Pezzella, Graham Steers, et al.
Cell Cycle (Georgetown, Tex.)|May 10, 2013
Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent mannerSue Haupt, Catherine Mitchell, Vincent Corneille, et al.
Cancer|October 30, 2003
Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase NetworkNaomi B Haas, Bruce J Giantonio, Samuel Litwin, et al.
Cancer Immunology Research|January 31, 2018
Prognostic Significance of PD-L1<sup>+</sup> and CD8<sup>+</sup> Immune Cells in HPV<sup>+</sup> Oropharyngeal Squamous Cell CarcinomaBenjamin Solomon, Richard J Young, Mathias Bressel, et al.
Asia-Pacific Journal of Clinical Oncology|October 9, 2018
Current mismatch repair deficiency tumor testing practices and capabilities: A survey of Australian pathology providersLyon Mascarenhas, Susan Shanley, Gillian Mitchell, et al.
Nature Genetics|April 15, 2008
No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomasWen Qiu, Min Hu, Anita Sridhar, et al.
Breast Cancer Research and Treatment|August 4, 2010
Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patientsTeresa Mele, Daniele Generali, Stephen Fox, et al.
Pageof 12

Showing results (61-70 of 119) with videos related to

Sort By:
Pageof 12
Cancer Prevention Research (Philadelphia, Pa.)|July 8, 2011
Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer familiesHeather Thorne, Amber J Willems, Eveline Niedermayr, et al.
The Lancet. Oncology|December 15, 2016
Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA studyStephen J Luen, Roberto Salgado, Stephen Fox, et al.
Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B|November 6, 2010
Establishment of the Australian in situ hybridization program for the assessment of HER2 amplification in breast cancer: a model for the introduction of new biomarkers into clinical practiceGelareh Farshid, Jane E Armes, Richard Bell, et al.
International Journal of Clinical and Experimental Pathology|January 1, 2015
Blood vessel invasion and other variables as predictors of long-term survival in Japanese and British patients with primary invasive breast cancerTakao Kato, Francesco Pezzella, Graham Steers, et al.
Cell Cycle (Georgetown, Tex.)|May 10, 2013
Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent mannerSue Haupt, Catherine Mitchell, Vincent Corneille, et al.
Cancer|October 30, 2003
Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase NetworkNaomi B Haas, Bruce J Giantonio, Samuel Litwin, et al.
Cancer Immunology Research|January 31, 2018
Prognostic Significance of PD-L1<sup>+</sup> and CD8<sup>+</sup> Immune Cells in HPV<sup>+</sup> Oropharyngeal Squamous Cell CarcinomaBenjamin Solomon, Richard J Young, Mathias Bressel, et al.
Asia-Pacific Journal of Clinical Oncology|October 9, 2018
Current mismatch repair deficiency tumor testing practices and capabilities: A survey of Australian pathology providersLyon Mascarenhas, Susan Shanley, Gillian Mitchell, et al.
Nature Genetics|April 15, 2008
No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomasWen Qiu, Min Hu, Anita Sridhar, et al.
Breast Cancer Research and Treatment|August 4, 2010
Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patientsTeresa Mele, Daniele Generali, Stephen Fox, et al.
Pageof 12